252 related articles for article (PubMed ID: 27354216)
1. Neutralizing capacity of inhibitors on FVIII is lower for natural FVIII/VWF complex than for isolated FVIII: in vitro comparative study in eleven different therapeutic FVIII concentrates.
Bravo MI; Ortiz AM; Costa M; Grancha S; Jorquera JI
Haemophilia; 2016 Jul; 22(4):e341-4. PubMed ID: 27354216
[No Abstract] [Full Text] [Related]
2. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
3. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
Berntorp E
Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
[TBL] [Abstract][Full Text] [Related]
4. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
Franchini M; Lippi G
Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
[TBL] [Abstract][Full Text] [Related]
5. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
6. Immune tolerance induction in patients with hemophilia A.
Astermark J
Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
[TBL] [Abstract][Full Text] [Related]
7. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
Mathieu S; Crampe C; Dargaud Y; Lavigne-Lissalde G; Escuriola-Ettingshausen C; Tardy B; Meley R; Thouvenin S; Stephan JL; Berger C
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein.
Ragni MV; Alabek M; Malec LM
Haemophilia; 2016 Sep; 22(5):e462-4. PubMed ID: 27501368
[No Abstract] [Full Text] [Related]
9. Management of bleeding disorders: basic science.
Ofosu FA; Santagostino E; Grancha S; Marco P
Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
[TBL] [Abstract][Full Text] [Related]
10. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.
Gringeri A
Haemophilia; 2007 Dec; 13 Suppl 5():73-7. PubMed ID: 18078402
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
[TBL] [Abstract][Full Text] [Related]
12. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
Ettingshausen CE; Kreuz W
Haemophilia; 2006 Dec; 12 Suppl 6():102-6. PubMed ID: 17123402
[TBL] [Abstract][Full Text] [Related]
13. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
[TBL] [Abstract][Full Text] [Related]
14. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
15. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.
Goudemand J
Haemophilia; 2007 Dec; 13 Suppl 5():47-51. PubMed ID: 18078397
[TBL] [Abstract][Full Text] [Related]
17. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
Santagostino E
Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
19. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients.
Kallas A; Talpsep T
Haemophilia; 2001 Jul; 7(4):375-80. PubMed ID: 11442642
[TBL] [Abstract][Full Text] [Related]
20. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
